[Other] MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study

dehaya Post time Half hour(s) ago | Show all posts |Read mode
This post will be closed automatically in 2026-07-31 17:44
Reward10points

THE LANCET ONCOLOGY

Articles Volume 27, Issue 3p349-360 March 2026

MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study


Fleur M Louis, MDa ∙ Anna van der Voort, MDa ∙ Mette S van Ramshorst, MDa ∙ Antonios Daletzakis, PhDb ∙ Ingrid A Mandjes, MScb ∙ Inge Kemper, MANPa ∙ et al. Show more

Affiliations & Notes
Article Info
Publication History:
Published February 16, 2026
DOI: 10.1016/S1470-2045(25)00707-7 External Link
Also available on ScienceDirect External Link
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

You have to log in before you can reply Login | Register

Points Rules

Senior Member
  • post

  • reply

  • points

    1510

Return to the list